The FDA has approved Insmed’s Brinsupri (brensocatib), the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB). This DPP-1 inhibitor offers a new therapeutic option for an estimated 500,000 U.S. patients suffering from this chronic lung disease characterized by dilated airways and persistent infections. The approval follows a pivotal Phase 3 trial demonstrating significant delay in disease exacerbations. Insmed plans to launch Brinsupri commercially with doses of 10 mg and 25 mg, positioning it as a potential blockbuster drug in respiratory medicine.